Status:
COMPLETED
Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit
Lead Sponsor:
Radboud University Medical Center
Conditions:
Invasive Fungal Infections
Pharmacokinetics
Eligibility:
All Genders
18+ years
Brief Summary
20 patients admitted to the ICU department and receiving isavuconazole as part of standard care for the treatment of fungal infections will be included in the study. Between day 3 and 7, 8 samples wil...
Detailed Description
Fungal infections are a serious threat to immunocompromised patients and represent a major burden in the critical care setting. The azole antifungal drugs are the most important drugs for managing inf...
Eligibility Criteria
Inclusion
- Patient is admitted to an ICU
- Is treated with isavuconazole intravenously (iv)
- Subject is at least 18 years on the day of the first dosing
- Is managed with a central venous catheter or arterial line
Exclusion
- Patient has previously participated in this study
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04777058
Start Date
March 1 2021
End Date
September 29 2022
Last Update
October 26 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Leuven
Leuven, Belgium
2
Jeroen Bosch Hospital
's-Hertogenbosch, Netherlands
3
Radboud University Medical Centre
Nijmegen, Netherlands
4
University Medical Center Utrecht
Utrecht, Netherlands